Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection has driven strong sales, contributing to the company’s overall revenue ...
4d
Viking Therapeutics (VKTX): Rethinking Valuation After a Sharp Pullback and Strong Multi‑Year Run
Viking Therapeutics (VKTX) has been on a wild ride this year, with shares sliding over the past month even after a massive run in the past 3 years. So what is the market rethinking here? See our ...
Upstart biotech company Viking Therapeutics ( VKTX 3.98%) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its ...
For those willing to take a chance, let's consider two biotech stocks that could eventually become solid, well-established drugmakers: CRISPR Therapeutics(NASDAQ: CRSP) and Viking Therapeutics(NASDAQ: ...
Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord ...
An investment strategist has outlined ten sub-$10 billion market-cap companies he believes are positioned to benefit heading ...
With all of this in mind, let's check out my top 10 stocks to buy for 2026. They offer you a balanced blend of ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks to buy according to Wall Street analysts. On ...
In recent days, options scanners identified unusually large and mostly bullish options trades in Viking Therapeutics, pointing to elevated interest from major investors. This burst of complex options ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has ...
Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from the wider excitement in obesity treatment area ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback